<DOC>
	<DOCNO>NCT00853385</DOCNO>
	<brief_summary>This comparative study CP 690,550 , Humira ( adalimumab ) placebo background methotrexate patient Rheumatoid Arthritis . The study intend provide evidence efficacy safety CP 690,550 dose 5 mg 10 mg twice day background methotrexate adult patient moderate severe Rheumatoid Arthritis . It intend confirm benefit CP-690,550 improve sign symptom physical function observe Rheumatoid Arthritis . An active comparator , adalimumab , also include .</brief_summary>
	<brief_title>A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator , Humira ( Adalimumab ) Vs . Placebo For Treatment Of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The patient diagnosis RA base upon American College Rheumatology ( ACR ) 1987 Revised Criteria . The patient must inadequate response methotrexate active disease , define : ≥6 joint tender painful motion ; ≥6 joint swell ; fulfills 1 follow 2 criterion Screening : 1.ESR ( Westergren method ) &gt; 28 mm local laboratory . 2 . CRP &gt; 7 mg/L central laboratory . No evidence active latent inadequately treated infection Mycobacterium tuberculosis . The patient must stable dose 7.5 mg 25 mg weekly methotrexate wash DMARDs . Blood dyscrasias include confirm : 1 . Hemoglobin &lt; 9 g/dL Hematocrit &lt; 30 % ; 2 . White blood cell count &lt; 3,000 cu.mm . Absolute neutrophil count &lt; 1,200 cu.mm ; 4 . Platelet count &lt; 100,000/L History autoimmune rheumatic disease Sjogren 's syndrome No malignancy history malignancy . History infection require hospitalization , parenteral antimicrobial therapy , otherwise judge clinically significant investigator , within 6 month prior first dose study drug Patients fail TNFi either lack efficacy TNFi mechanism related adverse event . Patients previously receive adalimumab therapy reason . Patients contraindicate treatment adalimumab accordance approve local label . Patients meet New York Heart Association Class III Class IV Congestive Heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>oral DMARD</keyword>
	<keyword>JAK inhibitor</keyword>
	<keyword>clinical trial</keyword>
</DOC>